# Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of Age

> **NCT01156792** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 162 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** FP 100
- **DRUG:** GSK2190915 100
- **DRUG:** GSK2190915 300
- **DRUG:** montelukast
- **DRUG:** placebo
- **DRUG:** FP/SAL 100/50

## Key facts

- **NCT ID:** NCT01156792
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-09
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 162 (ACTUAL)
- **Last updated:** 2017-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01156792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01156792, "Safety and Efficacy Study of Adding GSK2190915 to Low Dose Inhaled Corticosteroid Treatment for Asthma Subjects > or = 12 Years of Age". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01156792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*